Coherus Oncology (CHRS) Change in Intangibles (2024)

Coherus Oncology's (CHRS) quarterly Change in Intangibles came in at $187.8 million in Q1 2024.

Coherus Oncology (CHRS) Change in Intangibles (2024) Analysis & Trends

Coherus Oncology has disclosed Change in Intangibles across 1 years of filings, most recently posting $187.8 million for Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Intangibles (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -2.96 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Coherus Oncology 199.14 Mn 32.09 Mn 8.50 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2024 187.82 Mn
Mar 31, 2024 187.82 Mn